Melane Sampson, Author at BioTuesdays

Developments

Profound reports positive perioperative data from randomized CAPTAIN trial comparing TULSA with Robotic Prostatectomy; Lake Street analyst suggests trial data will be well received by payors

Profound Medical (NASDAQ:PROF; TSX:PRN) announced initial perioperative data from its Level 1 post-market CAPTAIN trial comparing the safety and efficacy of the TULSA procedure with radical prostatectomy (RP) in men...

April 30, 2025

Developments

Immunic unveils positive data from Phase 2 trial of IMU-838 in progressive MS

Immunic (NASDAQ:IMUX) announced positive Phase 2 CALLIPER data demonstrating its nuclear receptor related 1 (Nurr1) activator—vidofludimus calcium (IMU-838)—reduced the risk of progressive multiple sclerosis (PMS)...

April 30, 2025

Feature

Tasman redefining treatment for hard-to-treat depression with breakthrough oral ketamine monotherapy

Closely held Tasman Therapeutics is shifting the treatment landscape for treatment-resistant depression (TRD) with its registered, proprietary formulation—a first-of-its-kind, oral extended-release ketamine tablet.

April 29, 2025

Executive Moves

Modivcare appoints Daniel Silvers to BOD; three BOD members resign

Modivcare (NASDAQ:MODV) announced that it has appointed Daniel Silvers to its board of directors (BOD), and board members Craig Barbarosh, David Coulter, and Richard Kerley have resigned, effective April 24, 2025. Mr...

April 25, 2025

Developments

Polyrizon reports positive safety study of allergy blocker

Polyrizon (NASDAQ:PLRZ) announced the successful preliminary safety study of a formulation of its PL-14 Allergy Blocker, advancing the product’s development path. According to Polyrizon, the study, designed to assess...

April 25, 2025

Developments

Ekso names Bionic P&O as first Ekso Indego Personal distributor within the orthotics and prosthetics industry

Ekso Bionics Holdings (NASDAQ:EKSO) announced it has selected Bionic Prosthetics & Orthotics Group (Bionic P&O) as a non-exclusive distributor of its Ekso Indego Personal device—the alliance marking Ekso’s first...

April 23, 2025

Developments

FDA clears Aclaris’ IND application for ATI-052 trial

Aclaris Therapeutics (NASDAQ:ACRS) announced that the FDA has cleared its Investigational New Drug (IND) application for a Phase 1a/1b trial of ATI-052—expected to launch in Q2 of this year. According to Aclaris, the...

April 22, 2025

Developments

USPTO grants Atossa patents strengthening breast cancer treatment portfolio

Atossa Therapeutics (NASDAQ:ATOS) announced that the USPTO has granted a new patent for enteric oral formulations comprising (Z)-endoxifen, including methods of treating patients. According to Atossa, the patent...

April 22, 2025

Developments

PharmaJet to present insights from DNA cancer vaccine partner trials at WVC 2025

Closely held PharmaJet announced it will present insights from several DNA cancer vaccine partner trials using PharmaJet’s Precision Delivery Systems at the World Vaccine Congress (WVC) on April 23, 2025 at 12:25 pm ET...

April 17, 2025

Feature

Arch advancing game-changing therapies for global kidney care

Arch Biopartners (TXSV:ARCH; QTCQB:ACHFF) is at the forefront of developing breakthrough therapies to combat acute kidney injury (AKI) and prevent organ damage. By targeting the dipeptidase-1 (DPEP1) inflammation...

April 15, 2025

Author - Melane Sampson

Profound reports positive perioperative data from randomized CAPTAIN trial comparing TULSA with Robotic Prostatectomy; Lake Street analyst suggests trial data will be well received by payors

Immunic unveils positive data from Phase 2 trial of IMU-838 in progressive MS

Tasman redefining treatment for hard-to-treat depression with breakthrough oral ketamine monotherapy

Modivcare appoints Daniel Silvers to BOD; three BOD members resign

Polyrizon reports positive safety study of allergy blocker

Ekso names Bionic P&O as first Ekso Indego Personal distributor within the orthotics and prosthetics industry

FDA clears Aclaris’ IND application for ATI-052 trial

USPTO grants Atossa patents strengthening breast cancer treatment portfolio

PharmaJet to present insights from DNA cancer vaccine partner trials at WVC 2025

Arch advancing game-changing therapies for global kidney care

Subscribe